Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma

Abstract

Background Diffuse intrinsic pontine glioma (DIPG) is a fatal childhood brainstem tumor for which radiation is the only treatment. Case studies report a clinical response to ONC201 for patients with H3K27M-mutant gliomas. Oncoceutics (ONC201) is only available in the United States and Japan; however, in Germany, DIPG patients can be prescribed and dispensed a locally produced compound—ONC201 German-sourced ONC201 (GsONC201). Pediatric oncologists face the dilemma of supporting the administration of GsONC201 as conjecture surrounds its authenticity. Therefore, we compared GsONC201 to original ONC201 manufactured by Oncoceutics Inc. Methods Authenticity of GsONC201 was determined by high-resolution mass spectrometry and nuclear magnetic resonance spectroscopy. Biological activity was shown via assessment of on-target effects, in vitro growth, proliferation, and apoptosis analysis. Patient-derived xenograft mouse models were used to assess plasma and brain tissue pharmacokinetics, pharmacodynamics, and overall survival (OS). The clinical experience of 28 H3K27M+ mutant DIPG patients who received GsONC201 (2017–2020) was analyzed. Results GsONC201 harbored the authentic structure, however, was formulated as a free base rather than the dihydrochloride salt used in clinical trials. GsONC201 in vitro and in vivo efficacy and drug bioavailability studies showed no difference compared to Oncoceutics ONC201. Patients treated with GsONC201 (n = 28) showed a median OS of 18 months (P = .0007). GsONC201 patients who underwent reirradiation showed a median OS of 22 months compared to 12 months for GsONC201 patients who did not (P = .012). Conclusions This study confirms the biological activity of GsONC201 and documents the OS of patients who received the drug; however, GsONC201 was never used as a monotherapy.

Diffuse Intrinsic Pontine Glioma: Molecular Landscape, Evolving Treatment Strategies and Emerging Clinical Trials

“…ONC201 is an immunostimulatory small molecule antagonist dopamine receptors (DRD2/3) that has been reported in a range of malignancies including H3 K27M -mutant DIPG/DMG [ 103 ]. In preclinical murine models, this has been shown to double the OS [ 104 ]. Currently, there is an ongoing phase 2 clinical trial that looks to assess its efficacy further in pediatric H3 K27M -mutant gliomas.…”

The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies

“…Furthermore, ACTs targeting the ganglioside GD2 as well as HER2 show promising preclinical results (discussed below). 69,70 Benefits-ACT success stories.…”

B-cell Lymphoma 6 (BCL6): From Master Regulator of Humoral Immunity to Oncogenic Driver in Pediatric Cancers

“…This is underpinned by sophisticated improvements to protocol-driven clinical trials that utilize combinations of chemotherapies that attempt to address the somatic and epigenetic heterogeneity of these cancers. However, for some of the most aggressive types of childhood malignancies, there remains no effective pharmacologic intervention and children succumb to their disease within a short timeframe (39,(43)(44)(45). As 35% to 40% of children's malignancies originate in cells of the lymphoid linage where BCL6 plays a critical role in their maturation, there is a potential for targeting BCL6 in combination with therapies focused on the recurring somatic alterations responsible for disease initiation and progression.…”

“…DMG. DMGs, including DIPG, are pediatric CNS tumors recognized as the most lethal of all children's cancers (44,45). Palliative radiotherapy is the only approved treatment, with median survival just 9 to 11 months postdiagnosis (79).…”